Literature DB >> 10227103

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

M A Lee1, K Jayathilake, H Y Meltzer.   

Abstract

Clozapine has been reported to improve selected aspects of cognitive function in neuroleptic-resistant schizophrenia. In this study, we report the first direct comparison of the effect of clozapine and typical neuroleptic drugs on cognitive function in neuroleptic-responsive schizophrenia. Sixty-four patients with recent onset, neuroleptic-responsive schizophrenia or schizoaffective disorder were randomly assigned to either clozapine (n = 35) or typical neuroleptics (n = 29) and followed for 12 months. They were administered a comprehensive cognitive test battery at baseline and at 6 weeks, 6 months and 12 months after initiating drug treatment. Treatment with clozapine improved psychomotor speed and attention [Digit Symbol Substitution Test (DSST)] and verbal fluency [Category Instance Generation and Controlled Word Association Test (CWAT)] at 6 weeks. The improvement in these measures was maintained throughout the 12-month period. Treatment with typical neuroleptics produced no sustained improvement in any cognitive measure, except for a tendency to improve delayed recall memory (Verbal List Learning Test). The improvement in the DSST and CWAT was significantly greater with clozapine treatment compared to that with typical neuroleptics. These improvements were not related to improvement in psychopathology. These results suggest that clozapine is superior to typical neuroleptics in improving specific types of cognitive function in recent onset, neuroleptic-responsive schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227103     DOI: 10.1016/s0920-9964(98)00145-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  18 in total

1.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.

Authors:  Philip D Harvey; Michael F Green; Susan R McGurk; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

3.  Cognitive effects of olanzapine treatment in schizophrenia.

Authors:  Susan R McGurk; M A Lee; K Jayathilake; Herbert Y Meltzer
Journal:  MedGenMed       Date:  2004-05-10

Review 4.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

5.  Adolescent stress leads to glutamatergic disturbance through dopaminergic abnormalities in the prefrontal cortex of genetically vulnerable mice.

Authors:  Yurie Matsumoto; Minae Niwa; Akihiro Mouri; Yukihiro Noda; Takeshi Fukushima; Norio Ozaki; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2017-07-29       Impact factor: 4.530

6.  Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2006-10-13       Impact factor: 13.382

7.  Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.

Authors:  Kelli M Jones; Ivar M McDonald; Clotilde Bourin; Richard E Olson; Linda J Bristow; Amy Easton
Journal:  Psychopharmacology (Berl)       Date:  2013-09-21       Impact factor: 4.530

Review 8.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

9.  The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Authors:  D M Weiner; H Y Meltzer; I Veinbergs; E M Donohue; T A Spalding; T T Smith; N Mohell; S C Harvey; J Lameh; N Nash; K E Vanover; R Olsson; K Jayathilake; M Lee; A I Levey; U Hacksell; E S Burstein; R E Davis; M R Brann
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

10.  Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.

Authors:  Tomiki Sumiyoshi; A Roy; C-H Kim; K Jayathilake; M A Lee; C Sumiyoshi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.